VRM
AGN

Vectors Research Management’s Allergan plc AGN Stock Holding History

Vectors Research Management’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-65
Closed -$10K – 443
2019
Q1 		$10K Buy
+65
New +$9.42K 0.01% 286

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LP
Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vectors Research Management's AGN Position: Q2 2019 in Review

Vectors Research Management sold out of Allergan plc (AGN) in Q2 2019, closing a stake of 65 shares — an estimated $10K sold.

Vectors Research Management first reported a position in AGN in Q1 2019 and held it in 1 quarter. The position peaked at $10K in Q1 2019. 971 funds tracked by Wall St. Rank hold AGN as of Q2 2019.

  • Vectors Research Management reported no remaining Allergan plc position as of Q2 2019 after selling out during the quarter.
  • Vectors Research Management sold 65 Allergan plc shares in Q2 2019, an estimated $10K.
  • Vectors Research Management first reported a position in Allergan plc in Q1 2019 and held it in 1 quarter.
  • Vectors Research Management's Allergan plc position peaked at $10K in Q1 2019.
  • 971 funds tracked by Wall St. Rank held Allergan plc as of Q2 2019.

Based on Vectors Research Management's 13F filing for Q2 2019, filed 12 Aug 2019.